Urinary
incontinence is a symptom of general lifestyle habits resulting in the loss of
bladder control which leads to involuntary urination. According to the study ‘URINARY
INCONTINENCE GLOBAL CLINICAL TRIALS
REVIEW, H1, 2018’, the severity ranges from occasionally leaking
urine on coughing or sneezing to having an urge to urinate that is so sudden
and strong that you cannot get to a toilet in time. Though it occurs more often
as people get older, urinary incontinence is not an inevitable consequence of
aging. For affected people, simple lifestyle changes or medical treatment can
ease discomfort or stop urinary incontinence.
Medications
are available for people with bladder control issues. Anticholinergics are
drugs that block the action of the chemical messenger acetylcholine in the
central or peripheral nervous system responsible for sending signals to the
brain that cause abnormal bladder contractions associated with overactive
bladder. These drugs are widely used to tackle other ailments as well which
include depression, Parkinson’s disease and epilepsy among others. It is well
known that anticholinergics affect cognition and guidelines suggest they are to
be avoided among frail elderly people. Over the past years prolonged exposure
to anticholinergic drugs has been linked to long term cognitive decline
including dementia. However, these studies have been limited in their ability
to determine if the increased risk is specific to the anticholinergic action or
not. However, recent studies by BMJ company reveal that anticholinergic drugs
can significantly increase the susceptibility to dementia. CNN Health and
PsychCentral studies also support these findings.
Mirabegron,
marketed in the US as Myrbetriq, is a medication that relaxes the bladder
muscles and can increase the amount of urine the bladder can hold. It may also
increase the amount a person is able to urinate at one time, emptying the
bladder more completely. This drug reacts with other medication and recent
experimentation has led to some developments in this respect. In May 2018,
Tokyo based Astellas Pharma Inc. announced that the U.S. Food and Drug
Administration (FDA) has approved a supplemental New Drug Application (sNDA) for
the use of mirabegron in combination with the muscarinic antagonist,
solifenacin succinate for the treatment of overactive bladder (OAB) with
symptoms of urinary incontinence. Astellas Pharma Inc. is a Japanese company
dedicated to improving the health of people around the world through the
provision of innovative and reliable pharmaceutical products with urology being
one of its focus sectors. The experts of their urology department believe that
OAB patients may have symptoms that may not be fully managed by their current
treatment but with the FDA approval of Myrbetriq in combination with solifenacin
succinate, Astellas will be able to offer an additional treatment option to
such people. These results have been based on data from the global Phase 3
SYNERGY 1, SYNERGY 2 and BESIDE studies. These studies had evaluated
combination therapy with mirabegron and solifenacin succinate. These results are
also proving safe as a controlled clinical safety study did not demonstrate
increased urinary retention in Myrbetriq patients however, there have been
other side effects noted.
Urinary
incontinence treatment drugs have revealed new long term effects. Such effects
are further being studied to give a deeper understanding to researchers. Since
the most popular drugs are affecting the nervous system, their true potential
is being carefully realized and approved, for safe use, by institutions such as
FDA. Pharmaceutical companies such as Astellas which is combining internal
capabilities with external expertise in the medical field appear at the
forefront of healthcare change to turn innovative science into value for
patients.
To know more, click on the link below:
Related Report:-
Contact Us:
Ken
Research
Ankur
Gupta, Head Marketing & Communications
+91-9015378249
No comments:
Post a Comment